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A B S T R A C T
Japanese encephalitis virus (JEV) remains a leading cause of encephalitis, globally, which continues to grow in
importance despite the availability of vaccines. Viral entry into the brain can occur via the blood-brain barrier
(BBB), and inﬂammation at the BBB is a common ﬁnal pathway in many brain infections. However, the role of
the BBB during JEV infection and the contribution of the endothelial and astrocytic cell inﬂammation in fa-
cilitating virus entry into the brain are incompletely understood. We established a BBB model using human brain
endothelial cells (HBECs) and human astrocytes. HBECs are polarised, and therefore the model was inoculated
by JEV from the apical side to simulate the in vivo situation. The eﬀects of JEV on the BBB permeability and
release of inﬂammatory mediators from both apical and basolateral sides, representing the blood and the brain
side respectively were investigated. JEV infected HBECs with limited active virus production, before crossing the
BBB and infecting astrocytes. Control of JEV production by HBECs was associated with a signiﬁcant increase in
permeability, and with elevation of many host mediators, including cytokines, chemokines, cellular adhesion
molecules, and matrix metalloproteases. When compared to the controls, signiﬁcantly higher amounts of
mediators were released from the apical side as opposed to the basolateral side. The increased release of
mediators over time also correlated with increased BBB permeability. Treatment with dexamethasone led to a
signiﬁcant reduction in the release of interleukin 6 (IL6), C-C motif chemokine ligand 5 (CCL5) and C-X-C motif
chemokine ligand 10 (CXCL10) from the apical side with a reduction in BBB disruption and no change in JEV
production. The results are consistent with the hypothesis that JEV infection of the BBB triggers the production
of a range of host mediators from both endothelial cells and astrocytes, which control JEV production but disrupt
BBB integrity thus allowing virus entry into the brain. Dexamethasone treatment controlled the host response
and limited BBB disruption in the model without increasing JEV production, supporting a re-investigation of its
use therapeutically.
1. Introduction
Encephalitis is inﬂammation and swelling of the brain, which can be
caused by a range of viruses, often with devastating results (Solomon
et al., 2014). Globally JEV is one of the most important causes. Al-
though largely conﬁned to South and East Asia, this mosquito-borne
ﬂavivirus (genus Flavivirus, family Flaviviridae) has spread to the
northern territories of Australia and potentially to European countries
with the recent discovery of JEV RNA in mosquitoes in northern Italy
(Ravanini et al., 2012). The virus is closely related to West Nile virus
(WNV) and Zika virus; the former causes encephalitis in a small pro-
portion of patients; the latter has caused large outbreaks of febrile
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illness and congenital brain disease in Latin America (Vasilakis &
Weaver, 2017). There are an estimated 67,000 cases of Japanese en-
cephalitis (JE) annually with 13–24,000 deaths (Campbell et al., 2011).
In addition, more than half the survivors have severe neurological se-
quelae, posing a large economic and health burden on the communities
aﬀected (Gould & Solomon, 2008). Vaccines are available for JEV, but
their use is limited by cost and availability, especially in many low-
middle income countries where JEV is endemic (McArthur & Holbrook,
2011). There is currently no speciﬁc treatment for JEV or indeed any
ﬂavivirus. Dexamethasone is sometimes used to control brain swelling,
although a small trial in Thailand failed to show any beneﬁt (Hoke
et al., 1992). Furthermore, corticosteroids such as hydrocortisone and
dexamethasone in low doses (nM range) have also been shown to im-
prove BBB integrity in vivo (Salvador et al., 2014) and in vitro (Deli
et al., 2005).
JEV is transmitted naturally in an enzootic cycle between birds,
pigs, and other vertebrate hosts by Culexmosquitoes. Humans are dead-
end hosts. Following inoculation during the bite of a blood-feeding
mosquito, JEV is thought to replicate in the skin and local lymph nodes,
causing a transient low viraemia, before crossing the BBB to gain entry
into the central nervous system (CNS) (Turtle & Solomon, 2012). How
exactly JEV crosses the BBB to enter the CNS is not known, but three
routes are possible: passive transport of whole virions across the en-
dothelium, replication of virus within the endothelium, or a “Trojan
horse” mechanism (diapedesis) of infected leukocytes between en-
dothelial cells (Solomon & Vaughn, 2002). BBB damage due to in-
ﬂammation is thought to be a common ﬁnal pathway in many brain
infections, allowing pathogens and immune cells access into the brain,
and leading to CNS damage (Miner & Diamond, 2016). At autopsy,
histopathological changes of inﬂammation, including BBB breakdown
and inﬁltration of leukocytes are common in JE, and the anti-in-
ﬂammatory corticosteroid drug dexamethasone is sometimes given in
an attempt to control this (Hoke et al., 1992). However, the extent to
which this inﬂammatory response actually contributes to viral entry
across the human BBB is unclear. A better understanding of the means
by which JEV crosses the BBB, and the contribution of the host response
to this may point the way towards developing new therapeutic ap-
proaches not only for JEV but also for similar ﬂaviviruses such as WNV
and Zika virus.
Although animal models can provide useful insights into the pa-
thogenesis of encephalitis (Liu et al., 2008; German et al., 2006; Mishra
et al., 2009; Myint et al., 1999), their applicability to the human BBB is
limited. There are considerable species-speciﬁc diﬀerences in BBB, in-
cluding diﬀerent expression levels and functionalities of BBB trans-
porters, diﬀerences in BBB metabolic enzyme activities, amyloid-beta
clearance rates, and timing of BBB maturation, to name a few
(Vogelgesang & Jedlitschky, 2014; Qosa et al., 2014; Syvänen et al.,
2009; Chu et al., 2013; Deo et al., 2013; Semple et al., 2013). In vitro
models of the human BBB provide greater ﬂexibility for studying the
BBB in detail, allow mechanistic insight into the cross talk between
virus and the brain endothelium, and give additional physiologically
relevant human data, while reducing the reliance on animal models.
Cultured human brain endothelial cells tend to lose some BBB features
(e.g. reduced expression of tight junction proteins, transporters, re-
ceptors and enzymes) after extraction, but most can be induced by
using specialised growth medium containing soluble diﬀerentiation
factors and by co-culturing with astrocytes and/or pericytes
(Patabendige, 2012). We therefore established a co-culture model of the
human BBB (Ferguson et al., 2015) using a well-characterised human
brain endothelial cell line (Wassmer et al., 2006) and primary human
astrocytes. Using this model, we examined the eﬀects of JEV infection
in HBECs and the associated pro-inﬂammatory host response on the
BBB integrity, and investigated the impact of the corticosteroid drug
dexamethasone on these parameters.
2. Material and methods
2.1. Establishment of the in vitro human BBB model
HBECs were kindly provided by Georges Grau (University of Sydney
Medical School) and were used up to passage 20 (Wassmer et al., 2006).
HBECs were grown in collagen-coated ﬂasks and maintained in Dul-
becco's Modiﬁed Eagle's Medium (DMEM) containing 2mM glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, and 550 nM hydro-
cortisone (Sigma, UK), 10% fetal bovine serum (FBS) and human re-
combinant epidermal growth factor (First Link, UK). Primary human
astrocytes were purchased from ScienCell (USA) and were used at
passage 2–5. Human astrocytes were grown in ﬂaks coated with poly-D-
lysine and were maintained in DMEM/Ham's Nutrient Mixture F12
(Sigma, UK) containing 10% FBS, 2mM glutamine and 100 U/ml pe-
nicillin, 100 μg/ml streptomycin. Cells were maintained in 5% CO2
humidiﬁed atmosphere at 37°C and were passaged every 3–4 days and
the culture medium replaced every 2–3 days. To set up the co-culture
BBB model, HBECs were seeded on collagen-coated Transwell-Clear
inserts (Corning, USA) at 1.0× 105 cells/insert (0.4 μm pores, 1 mm
diameter, 0.5 ml) and were transferred to a 12-well plate containing
conﬂuent human astrocytes (1.0× 105 cells/well, 1.5 ml) as described
previously (Ferguson et al., 2015). Experiments were performed when
HBECs were conﬂuent and when transendothelial electrical resistance
(TEER, a functional measurement of BBB integrity) of the model was
over 50Ω·cm2.
2.2. Transendothelial electrical resistance measurements
TEER across the BBB model was determined using STX100C elec-
trodes connected to an EVOM2 epithelial voltohmmeter (World
Precision Instruments, UK) as described previously (Patabendige &
Abbott, 2014; Patabendige et al., 2013a). The resistance of cells grown
on Transwell ﬁlter inserts was corrected for resistance across a cell-free
insert, and multiplied by surface area, to give TEER in ohms x cm2
(Ω·cm2).
2.3. Infecting cells with JEV
A strain of JEV (CNS138-11, GenBank accession no: AY184213)
isolated from the brain of a fatal human case in 1999 from Sarawak,
Malaysian Borneo was used for all experiments (Solomon et al., 2003).
JEV was propagated in Vero cells, harvested at 5–6 days post inocula-
tion, and titrated by plaque formation in Vero cells. In brief, six well
plates were inoculated with 10-fold dilutions of JEV and left to adsorb
for 1 h before an agarose overlay of Minimum Essential medium (MP
Biomedicals, UK) containing 5% FBS was added. The cells were in-
cubated at 37 °C for 5–6 days, ﬁxed, and plaques were visualised by
crystal violet staining. The BBB model was infected with JEV from the
apical (blood) side at a multiplicity of infection (MOI) of 1 for one hour
and fed with fresh media. Virus diluent media (DMEM with 2% FBS)
was used for mock-infected controls. Samples were taken immediately
post infection and at serial time points from both the apical and baso-
lateral (brain) sides for cytokine analysis or plaque assays. TEER was
measured before infection and then at serial time points post infection.
To determine the eﬀectiveness of the human BBB model in restricting
JEV entry, the Transwell system was set up as described in co-cultures,
monocultures of either HBECs only or human astrocytes only and cell-
free inserts. The system was inoculated with JEV (MOI=1) from the
apical side and samples were taken at serial time points post infection
from both apical and basolateral sides. For the JEV growth curve,
HBECs were infected as described above and supernatants were col-
lected at 0–4 days post infection. Infectious virus particles were quan-
tiﬁed by plaque assay on Vero cells.
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2.4. Transmission electron microscopy
For transmission electron microscopy, JEV-infected cells were ﬁxed
with 5% glutaraldehyde in 0.1 M sodium cacodylate. Pellets were then
ﬁxed in 1% Osmium tetroxide, stained with Uranyl acetate, dehydrated
in a series of ethanols, acetone, inﬁltrated with araldite resin and
polymerised at 60 °C. Ultrathin Sections (60–90 nm) were cut with
‘Diatome’ diamond knife on ‘Reichert-Jung Ultracut’ ultramicrotome
(Leica Microsystems, UK) and mounted on 200 mesh copper grids and
stained with “Reynold's Lead citrate” stain. Images were captured using
Phillips EM208S transmission electron microscope at 80KV. Standard
EM/laboratory reagents and material were from TAAB Laboratories
Equipment Ltd., UK and Sigma.
2.5. Cytometric magnetic-bead array
Supernatants were taken from JEV-infected and mock-infected
controls from the apical and basolateral sides at 0, 6, 24 and 48 h post
infection. The inﬂammatory mediators were assessed using a com-
mercial cytometric magnetic-bead array assay system (Procarta
Immunoassay kit, Panomic Solutions, Aﬀymetrix Milano, Italy) in ac-
cordance with the manufacturer's instructions. The mediators assessed
were identiﬁed from previous literature; granulocyte-colony stimu-
lating factor (G-CSF), granulocyte macrophage-colony stimulating
factor (GM-CSF), interleukin (IL) 1α, IL1β, IL1-RA, IL4, IL6, IL10, IL13,
IL17a, IL17f, CXCL 8 (IL8), CXCL9, CXCL10, CCL2, CCL3, CCL4, CCL5,
CCL11, myeloperoxidase (MPO) Sap/Pentraxin 2, and tumour necrosis
factor (TNF), TNF-apoptosis-inducing ligand (TRAIL), interferon (IFN)
α2, β, γ, ο, leptin, vascular endothelial growth factor (VEGF), eSelectin,
granzyme B, intercellular adhesion molecule-1 (ICAM1), vascular cell
adhesion molecule (VCAM), matrix metalloproteinase (MMP)7, MMP8
and MMP9. Fluorescence intensity was determined using a Bio-Rad
platform (BioPlex Manager 4.1, Bio-Rad Laboratories, UK). Standards
and samples (two independent experiments in triplicates) were ana-
lysed in duplicate and the mean value used in analysis. Control samples
were pooled and analysed in duplicates. Standard curves were adjusted
at the points of ﬂuorescence intensity saturation, generating a sigmoid
curve with 6–8 points of ﬂuorescence intensity, as described previously
(Michael et al., 2013). To avoid undetectable levels of mediators
biasing the analysis, only mediators detected in at least 80% of the
samples were included in the analysis, as described previously (Michael
et al., 2016). The results were normalised to volume of the compart-
ments to give units in picogram (pg).
2.6. Dexamethasone treatment
Dexamethasone was purchased from Sigma, UK. TEER was mea-
sured in the BBB model as described above and infected with JEV
(MOI= 1) or mock-infected from the apical side. Cells were then
treated with 2 μg/ml dexamethasone. TEER was measured and samples
from both apical and basolateral sides were taken for analysis (n=3)
by a custom Multi-Analyte ELISArray kit from SABiosciences (Qiagen,
UK) for IL6, CCL5 and CXCL10 levels according to the manufacturer's
instructions. This kit allows a rapid assessment of the level of multiple
cytokines and chemokines in multiple samples over one standardised
development time. Absorbance reading at 450 nm was subtracted from
the absorbance reading at 570 nm to correct for artiﬁcially high signals.
The linear range of the assay is optical density readings between 0 and
2.5 at 450 nm for all analytes.
Samples from both apical and basolateral were also taken for ana-
lysis by plaque assay to determine JEV production as described earlier.
2.7. Statistical analysis
Data were expressed as mean ± standard error of the mean (SEM)
or mean ± standard deviation (SD) and analysed and presented using
Microsoft Excel 2007, 2010, or GraphPad Prism (versions 6 and 7)
software. Groups of two were analysed using Student's t-test, and two-
way ANOVA was used to analyse two independent variables. Values
were considered to be signiﬁcantly diﬀerent when the probability< 5%
(p < 0.05). All experiments were repeated at least 2–4 times. Overall
cytometric bead array mediator data from control and JEV infected
groups underwent a one-way hierarchical cluster analysis. Then med-
iator data from each group underwent Pearson's correlation nearest
neighbour analysis generating proximity matrices, using SPSS (SPSS
Inc., 2011); from these matrices, heat-maps were generated using
SigmaPlot (SigmaPlot, Systat Software Inc., USA); extraction heat-maps
were then generated by overlaying the proximity matrix from the JEV
infected model over the control, as described previously (Michael et al.,
2013). This generates a visual representation of the interaction of all
mediators and the extraction heat-map represents the diﬀerences be-
tween the two groups.
3. Results
3.1. JEV infects both human brain endothelial cells and astrocytes, and
increases BBB permeability with limited active viral production in
endothelial cells
Using electron microscopy, we were able to detect JEV particles
(40–50 nm diameter) in JEV-infected monocultures of HBECs (Fig. 1A)
and in human astrocytes (Fig. 1B) three days post infection (dpi). Im-
munoﬂuorescence experiments using an antibody against the JEV E
glycoprotein also conﬁrmed that JEV is able to infect HBECs and as-
trocytes (Supplementary Fig. 1).
Firstly, we assessed the virus production in monocultures of HBECs.
Plaque assays showed limited active viral production in HBECs (highest
JEV titre up to 1× 105 PFU/ml in HBECs cf. 1×107 in Vero cells,
where JEV was propagated). After an initial signiﬁcant rise in the
plaque forming units (PFU) at 2 dpi, the PFU declined following 3 dpi
(Fig. 2A). Therefore, we assessed the BBB permeability up to 4 dpi in
the co-culture model. Infection of the co-culture human BBB model
with JEV from the apical side led to a signiﬁcant drop in TEER 2 dpi
(p < 0.001), and remained at this level (Fig. 2B), indicating that BBB
integrity is lost early during infection, and the BBB permeability is not
increased despite further viral production within the endothelium.
3.2. Human brain endothelial cells act as an initial barrier to JEV
transmigration
We then assessed the barrier properties of HBECs to JEV transmi-
gration up to 2 dpi, given JEV titre/production signiﬁcantly increase by
2 dpi, and TEER does not decrease further after 2 dpi. Signiﬁcantly low
levels of infectious JEV particles were detected in the basolateral sides
of the culture systems with HBECs (Fig. 3A–B) compared to cultures
with astrocytes only (Fig. 3C) or in the cell-free inserts (Fig. 3D) im-
mediately post the inoculation period, indicating a barrier to JEV entry
to the basolateral compartment by the HBEC monolayer (Fig. 3). This
was further conﬁrmed by real-time RT-PCR experiments, where sig-
niﬁcantly lower amounts of viral mRNA (P < 0.01) were found on the
basolateral side compared to the apical side (Supplementary Fig. 2).
However, there was no signiﬁcant diﬀerence between apical and ba-
solateral levels of JEV in cultures with HBECs after 1–2 days post in-
fection (Fig. 3). Signiﬁcantly higher levels of JEV were detected
1–2 days post infection in astrocyte only cultures (Fig. 3C) on the ba-
solateral side compared to the apical side, indicating that JEV is able to
infect and replicate in human astrocytes. Not surprisingly, JEV pro-
duction continued to decline in the cell-free inserts after initial in-
oculation (Fig. 3D). Corresponding TEER data further demonstrate the
barrier properties of HBECs. Co-culture with human astrocytes
strengthened the barrier properties of HBECs, though TEER continued
to decline in both systems gradually (Fig. 3 A–B).
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3.3. JEV infection of the BBB model induces a strong pro-inﬂammatory
response from HBECs and astrocytes, with a signiﬁcant increase in mediator
release from the apical side compared to the basolateral side
Statistically signiﬁcant elevations in the levels of many in-
ﬂammatory mediators were found in both the apical and basolateral
side of the JEV infected BBB model in comparison to the control
(Table 1). In addition, when compared to the controls, many mediators
were detected at signiﬁcantly higher levels on the apical as opposed to
basolateral side. The majority of mediators demonstrated strong posi-
tive correlations with each other in both the JEV infected model and the
control, indicated in red on the heat-maps, suggesting a broad up-reg-
ulation of the production of all host-inﬂammatory mediators assessed in
concert (Fig. 4.). However, the extraction heat-maps demonstrated that,
in samples from the apical side as opposed to the basolateral side, many
more mediators had positive correlations in the JEV infected model
than the control, suggesting greater co-ordinated production of these
host-inﬂammatory mediators in the apical compartment. Nevertheless,
even on the basolateral side there were two broad clusters that corre-
lated positively within and between clusters, the ﬁrst included CCL5,
VEGF, and CXCL10, and the second cluster included VCAM, ICAM, and
IL-6. Interestingly, in the extraction heat-map of JEV-infected apical
and JEV-infected basolateral samples, there were several smaller clus-
ters. One included CXCX10 and MMP9 which had several positive
correlations, including with IL-1α. Another included G-CSF and CCL2,
and this had positive correlations with IL-1β. IL-6 had many negative
correlations, but had positive correlations with MMP7 and VEGF, sug-
gesting that in those samples IL-6 might be being up-regulated in co-
ordination with these other mediators.
3.4. Release of inﬂammatory mediators following JEV infection increases
with time and correlates with TEER
Several mediators, including IL6 (Fig. 5A), CCL5 (Fig. 5B) and
CXCL10 (Fig. 5C) signiﬁcantly increased with time following JEV in-
fection (two-way ANOVA; P < 0.001 for all three mediators). Many of
the mediators identiﬁed from the apical side were found to correlate
with TEER, including IL-6, CXCL10, VCAM and MMP7 (Table 2, Fig. 5D
and F). Fewer mediators were identiﬁed on the basolateral side to
correlate with TEER. Some mediators may cross the barrier as it be-
comes increasingly permeable and therefore correlation with TEER may
reﬂect this. Interestingly, excluding mediators present at higher levels
on the apical side, the mediators identiﬁed on the basolateral side that
had a signiﬁcant correlation with TEER were IL-6, CXCL10, VEGF,
ICAM and VCAM. In addition, to account for the potential for mediators
to cross the barrier as it becomes more permeable, we also measured
the total mediator level from both sides of the barrier and analysed for
any correlations with TEER. Signiﬁcant correlations with TEER were
found for many mediators including IL-6, CXCL10, VCAM, MMP7 and
leptin.
3.5. Dexamethasone treatment dampens the immune response and preserves
barrier integrity without signiﬁcant changes in infectious JEV levels
JEV infection led to a signiﬁcant increase in the levels of IL6, CCL5,
and CXCL10 in both apical and basolateral sides of the JEV infected
BBB model compared to the control (p < 0.05 to p < 0.001), in
agreement with the trend observed in the bead array experiment (data
not shown). Dexamethasone treatment signiﬁcantly reduced the levels
of all three mediators in the apical side (p < 0.05). However, only
Fig. 1. JEV is able to infect the cells forming the BBB. Conﬂuent monocultures of HBECs and human astrocytes were infected with JEV and ﬁxed at 3 days post
infection (dpi) at MOI= 1. Using electron microscopy, JEV particles (arrows) were detected in cytoplasmic vacuoles in both HBECs (A–B) and human astrocytes
(C–D); most were hexagonal in shape and 40–50 nm diameter with an electron dense core and an outer membrane (scale bar= 100 nm).
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CCL5 levels were signiﬁcantly reduced (p < 0.01) in the basolateral
side following dexamethasone treatment (Fig. 6D). The JEV-induced
disruption to the BBB integrity was signiﬁcantly reduced by dex-
amethasone treatment (Fig. 7A). Dexamethasone treatment did not
cause a signiﬁcant change in the levels of infectious JEV particles in
both apical and basolateral sides compared to untreated cultures
(Fig. 7B).
4. Discussion
JE is one of the most important causes of encephalitis globally, with
an estimated 67,000 cases annually, for which there is no established
treatment (Campbell et al., 2011). An improved understanding of the
mechanistic steps during CNS entry of JEV is pivotal to developing
targeted anti-inﬂammatory treatment. This study using an in vitro
model of the human BBB, has demonstrated that JEV, even at low titres
(MOI= 1 in current study cf. MOI=10–20 in published studies), can
infect human brain endothelial cells and initiate limited virus produc-
tion; however, this appears to activate the endothelium, as shown by
the release of many host pro-inﬂammatory mediators from both apical
and basolateral sides, leading to increased permeability of the BBB and
subsequent viral transmission across it. We found increased levels of
pro-inﬂammatory mediators in the apical side compared to the
basolateral side, and increased BBB permeability correlated with levels
of several mediators, especially in the apical side. Dexamethasone
treatment post JEV inoculation led to a signiﬁcant reduction in some of
the pro-inﬂammatory mediators that were assessed, and reduced the
JEV-induced BBB disruption. The anti-inﬂammatory action of dex-
amethasone did not lead to uncontrolled JEV production.
Currently, there is limited understanding of the role of the BBB
during JEV infection, including previous conﬂicting reports from
human autopsy studies on whether JEV can indeed infect human brain
endothelial cells and astrocytes (German et al., 2006; Iwasaki et al.,
1986). Here, we have demonstrated in an in vitro model of the BBB that
JEV is able to infect human brain endothelial cells and cross the BBB.
The results suggest that active production of virions in the endothelium
only occurs very early during infection and is not sustained. This initial
limited ability to replicate in endothelial cells, followed by an eﬀective
shut-down, may explain the diﬀering results from human autopsy stu-
dies (i.e. inability to access human brain tissue during the early stages of
JEV infection). Several studies on in vitro rat models have shown that
even when high titres of JEV (MOI=20) are used, there are limited
levels of virions in brain endothelial cells compared to BHK21 cells
(MOI=5) (Lai et al., 2012; Chen et al., 2014). We found the limited
production of JEV when infected with at an MOI of 1 within HBECs is
associated with upregulation of host inﬂammatory markers and in-
creased permeability of the BBB model, as demonstrated by a sig-
niﬁcant drop in TEER at 2 dpi. This increased permeability, re-
presenting disruption to the barrier integrity of endothelial cells,
appears to provide a route for further viral entry into the CNS. As
mentioned in the introduction, there are three potential routes for JEV
entry into the brain, and we investigated the possibility of the ﬁrst two
routes: passive transport of whole virions across the endothelium, and
replication of virus within the endothelium. Our results suggest passive
diﬀusion of the virus across the BBB following barrier disruption is
likely, though due to the leakiness of in vitro BBB models compared to
the in vivo BBB, deﬁnitive proof of this mechanism in in vitro models is
diﬃcult to obtain. However, as we have clearly shown infectious JEV
particle production in HBECs, and given that barrier integrity is not
compromised 2 dpi despite increasing viral titres, it is possible that JEV
infects and replicates in HBECs before inﬁltrating the brain.
It has been suggested that the pro-inﬂammatory mediators pro-
duced in peripheral tissues to control virus replication in animal models
of ﬂavivirus encephalitis could be increasing the BBB permeability, thus
allowing viral particles and virus-infected leukocytes to enter the brain
(Diamond & Klein, 2004). However, it is still not clear which cell types
are the key producers of inﬂammatory mediators in vivo that contribute
to increased BBB permeability. Here we show using an in vitro human
co-culture BBB model that cells within the BBB themselves generate this
strong, local inﬂammatory response. Interestingly, a recent study sug-
gests that JEV interferes with the apoptotic pathways in transfected
human brain microvascular endothelial cells, perhaps to prolong the
period during which viral replication can occur (Al-Obaidi et al., 2017).
A previous clinical study and work from a macaque model from our
group (Winter et al., 2004; Myint et al., 2014), and several studies on
mouse models (Kim et al., 2016; Shukla et al., 2016; Biswas et al., 2010;
Chen et al., 2012; Gupta et al., 2010) have shown the importance of
pro-inﬂammatory mediators during JEV infection. In WNV infected
mice, detection of the virus triggered the host tissue to induce an innate
immune response at the BBB, leading to increased BBB permeability
and virus transmigration. However, the detection of the virus in the
CNS coincided with a decrease in BBB permeability (Daniels et al.,
2014). This biphasic nature of BBB permeability after viral infection
suggests that viral and host factors contribute to a potentially diﬀer-
ential regulation of the BBB over the course of infection. Furthermore,
studies on an in vitro rat model have also shown that endothelial barrier
can be disrupted by pro-inﬂammatory cytokines released from JEV
infected pericytes and astrocytes (Chen et al., 2014; Chang et al., 2015).
Our study reports a detailed account of the levels of soluble mediators
Fig. 2. JEV is able to infect human brain endothelial cells with limited active
virus production, and increases BBB permeability. (A) JEV growth curve in
HBECs: HBEC monocultures were infected with JEV (MOI=1) and samples
were collected at serial time points from the apical side for analysis by plaque
assay. (B) BBB integrity was assessed by measuring transendothelial electrical
resistance (TEER) in the BBB model before infection (dpi= 0) and then at serial
time points following JEV infection (MOI= 1). Only cultures with TEER over
50Ω·cm2 were used. Results are mean TEER (% of control at each time
point ± SD). All experiments are n=2–3; student's t-Test, compared to day 0;
*P < 0.05, *P < 0.01, ***P < 0.001.
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released from both the apical and basolateral sides of the BBB, re-
presenting mediators released from the apical membrane of HBECs and
the sum of mediators released from the basolateral membrane of the
HBECs and astrocytes in response to JEV infection. However, passive
diﬀusion, and therefore, some exchange of these mediators between the
compartments is likely due to the low TEER of the human BBB model
compared to animal models with high TEER (Deli et al., 2005;
Patabendige, 2012), and further disruption to the BBB post-JEV infec-
tion. The evidence also supports a dual role for brain endothelial cells;
maintaining the integrity of the BBB, while contributing to its own
disruption by releasing inﬂammatory mediators during infection. The
release of pro-inﬂammatory mediators by brain endothelial cells is
important for attracting and traﬃcking leukocytes across the BBB
during infection. However, the release of these could exacerbate BBB
disruption, and open up a pathway for JEV to penetrate the brain.
Although corticosteroids are sometimes used across Asia for patients
with JE, their role is unclear. Furthermore, concerns regarding in-
creased viral replication and spread due to the immunosuppressive
Fig. 3. Barrier properties of the human
BBB model following JEV infection. To
assess the eﬀectiveness of the barrier
properties of the BBB model and to
quantify JEV production and cross
over, Transwells were set up as (A) co-
cultures with HBECs grown on the in-
serts with astrocytes in the well, (B)
monocultures of either HBECs only on
the inserts or (C) astrocytes only in the
well with a cell-free insert on top, and
(D) cell-free inserts/wells as blanks.
The apical side was inoculated with
JEV (MOI=1). TEER (box and whis-
kers) was measured ﬁrst, and then
samples were taken at serial time
points from both sides for analysis by
plaque assay. Results are mean ± SD
(n=3). Student's t-Test, comparing
apical (black bars) and basolateral
(white bars) sides; *P < 0.05,
**P < 0.01.
Table 1
Comparison of inﬂammatory mediators released in control and JEV-infected human BBB models over 48 h.
Mediator Basolateral (pg) Apical (pg) Basolateral vs. Apical JEV
JEV mean (SD) Control mean (SD) JEV vs. control P value JEV mean (SD) Control mean (SD) JEV vs. control P value P value
GCSF 24.47 (2.43) 10.62 (1.44) < 0.001 13.64 (6.68) 3.988 (0.70) <0.05 < 0.001
IFNβ 32.93 (5.84) 16.26 (1.79) < 0.001 12.74 (1.05) 6.352 (1.85) <0.001 <0.001
IFNο 1.325 (1.78) 0.6366 (0.22) < 0.001 0.4259 (0.04) 0.2371 (0.09) <0.001 <0.001
IL1α 8.498 (5.37) 2.924 (1.81) NS 9.634 (7.77) 2.185 (0.75) NS NS
IL1β 9.292 (1.65) 4.607 (1.03) < 0.001 3.581 (0.38) 1.766 (0.50) <0.001 <0.001
IL4 12.09 (0.83) 5.874 (0.99) NS 5.093 (0.99) 2.442 (0.66) <0.001 <0.001
IL6 5018 (3577) 2110 (787.6) NS 3497 (1026) 360.2 (217.7) <0.001 NS
IL8 5944 (6388) 1984 (638.5) NS 9242 (9393) 484.3 (182) NS NS
IL10 2.035 (0.46) 0.9175 (0.18) < 0.001 1.037 (0.16) 0.2782 (0.04) <0.001 <0.001
CXCL 10 126.6 (163.8) 33.75 (37.2) NS 209.8 (220.5) 34.27 (31.17) NS NS
CCL2 10,113 (4855) 5860 (4194) NS 4503 (2221) 1202 (240) <0.05 < 0.05
CXCL9 5.178 (2.45) 2.436 (0.57) NS 2.452 (0.92) 0.6154 (0.13) <0.05 < 0.05
CCL3 6.362 (1.41) 2.697 (0.34) < 0.001 3.096 (1.05) 1.292 (0.44) <0.05 < 0.001
CCL5 643.5 (371.8) 366.4 (167.2) NS 744.9 (278.1) 264.8 (167.9) <0.05 NS
TRAIL 267.1 (115.9) 125 (26.72) < 0.05 162.3 (41.73) 34.19 (9.25) <0.001 <0.05
VEGF 1354 (887.8) 639.1 (353) NS 1301 (282.5) 148.7 (94.37) <0.001 NS
ICAM 516.6 (305.8) 284.3 (126.9) NS 621.3 (487.3) 249 (160) NS NS
IFNο 1.186 (0.48) 0.7116 (0.29) NS 0.4948 (0.18) 0.1637 (0.03) <0.05 < 0.05
MPO 78.09 (66.68) 25.37 (4.61) NS 22.18 (4.68) 8.993 (2.09) <0.001 <0.05
VCAM 89.95 (30.26) 65.34 (15.88) NS 74.52 (51.29) 34.97 (14.33) NS NS
MMP7 235 (109.1) 124.6 (47.26) NS 85.52 (26.78) 30.66 (10.17) <0.05 < 0.05
MMP8 105.1 (87.56) 39.33 (8.33) NS 32.94 (8.41) 12 (3.97) <0.001 <0.05
MMP9 6.226 (6.96) 2.047 (0.40) NS 1.762 (0.37) 0.7931 (0.17) <0.001 NS
Leptin 98.38 (27.72) 41.79 (43.18) < 0.05 31.93 17.66) 12.62 (6.22) NS <0.001
IL17 6.457 (0.57) 3.249 (0.30) < 0.001 2.529 (0.57) 1.45 (0.71) <0.05 < 0.001
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actions of corticosteroids have limited their use in treating viral en-
cephalitis. One small randomised controlled trial showed that use of
corticosteroids was associated with a reduction in the cerebrospinal
ﬂuid opening pressure, and number of leukocytes in the spinal ﬂuid, but
failed to show any diﬀerence in clinical outcomes, partly because of the
small number of patients (Hoke et al., 1992; Johnson et al., 1986). The
most recent report on a large non-randomised study involving 1199 JE
patients, out of whom 737 were treated with dexamethasone did not
demonstrate a signiﬁcant diﬀerence in mortality (Sarkari et al., 2012);
however, a signiﬁcant improvement in mortality was observed when
the patients presenting with pulmonary oedema were excluded. There
is some evidence from animal studies that suggests using corticosteroids
as a treatment post infection with viruses such as herpes simplex virus
(HSV) or enterovirus 71 (EV71), leads to accelerated virus production
and increased mortality. However, the timing of the treatment appears
critical (Shen et al., 2014; Sergerie et al., 2007). Early treatment with
steroids maybe harmful in vivo due to the possibility of corticosteroids
aﬀecting the ability of immune cells to clear virus. In clinical ob-
servations and animal research on herpes simplex encephalitis (HSE),
steroids had no inﬂuence on viral replication and dissemination; and
retrospective study suggested that they might be beneﬁcial (Sergerie
et al., 2007; Thompson et al., 2000; Meyding-Lamade et al., 2003;
Kamei et al., 2005; Lizarraga et al., 2013). A multicentre randomised
controlled clinical trial on the use dexamethasone in HSE is underway
(www.dexenceph.org.uk). Given our observations on the beneﬁcial ef-
fects on BBB integrity and no signiﬁcant increase in JEV production, the
potential of dexamethasone and/or other corticosteroids as a treatment
against JE may merit further investigation.
Previous work from our group has shown that increased levels of
CSF IL6 and plasma CCL5 in JE patients were associated with a poor
outcome (Winter et al., 2004). The importance of CCL5 in increasing
the adhesion and migration of leukocytes across the BBB has been de-
monstrated in a rat brain endothelial cell model infected with JEV (Lai
et al., 2012); however, in that study there were no permeability changes
in the BBB, which was attributed to it being a mono-culture model using
a high MOI of JEV for inoculation (MOI=20). Recently, the same
group has shown that rat brain endothelial cells co-cultured with
pericytes released IL6 and caused disruption to the BBB, again using a
high titre (MOI=20) of JEV to infect pericytes (Chen et al., 2014).
They have also shown the release of IL6, VEGF and MMP2/9 from rat
astrocytes infected with JEV in a BBB co-culture model using a high
titre of JEV (MOI=20), which led to a disruption of tight junctions of
the BBB (Chang et al., 2015). These studies demonstrated a reduction in
the release of cytokines/chemokines when JEV is heat/UV inactivated,
suggesting that active virus is required to induce the release of these
pro-inﬂammatory mediators during JEV infection. Intriguingly, a recent
study using JEV on transfected human brain microvascular endothelial
cells has reported that the integrity of the cell monolayer was MOI-
dependent (0.5 to 10). However, JEV replication levels were not qua-
nitiﬁed in these cells (Al-Obaidi et al., 2017). Furthermore, another
study on mice infected with JEV has also demonstrated high levels of
inﬂammatory mediators (including IL6, CCL5 and CXCL10) in the brain
before JEV was detected. Applying brain extracts from these mice on
the mouse brain endothelial cell line, bEnd3 signiﬁcantly increased
bEnd3 endothelial cell permeability, but not when the brain extracts
were UV-inactivated, suggesting that inﬂammatory mediators rather
than JEV itself were most likely to be responsible for the increased
permeability of the BBB (Li et al., 2015). The importance of IL6 during
Fig. 4. JEV infection of the BBB induces a strong pro-inﬂammatory response from host cells. The BBB model was infected with JEV (MOI=1) from the apical side
and supernatants were collected at serial time points from both apical and basolateral sides for analysis by cytometric bead array to detect inﬂammatory mediators
(n=2). Heat-maps of nearest-neighbour correlations of cytokines and chemokines for the (A) JEV basolateral, (B) control basolateral, (C) basolateral JEV-control
extraction, (D) JEV apical, (E) control apical, (F) apical JEV-control extraction, and (G) JEV apical-basolateral extraction heat-maps. Red indicates a positive
correlation (+1), green a negative correlation (−1), and black as no correlation (0). Therefore, whilst the diagonal white line simply represents the correlation of
each mediator with itself (i.e. +1) that is excluded from analysis, the rest of the heatmap provides a visual representation of the positive or negative correlations of
each mediator with each other.
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Fig. 5. JEV Infection increases the release of several inﬂammatory mediators over time and correlates with TEER. The BBB model was infected with JEV (MOI= 1)
from the apical side, TEER measured and supernatants were collected at serial time points (0–2 dpi) from both apical (black bars) and basolateral (white bars) sides
for analysis by cytometric bead array. Grey bars indicate total amounts. JEV Infection signiﬁcantly increased the release of many mediators including, (A) IL6, (B)
CCL5 and (C) CXCL10 over time (n=2; two-way ANOVA P < 0.001 for all three mediators). Correlation of the release of (D) IL6, (E) CCL5 and (F) CXCL10 from
apical (dashed line), and basolateral (dotted line) sides, and the total amounts (continuous line) with TEER at the corresponding serial time points as shown for A-C
(n=2).
Table 2
Signiﬁcant correlations of inﬂammatory mediators with TEER following JEV infection.
Mediator Basolateral P value Apical P value Total P value
Pearson's correlation Pearson's correlation Pearson's correlation
GCSF −0.015 NS −0.925 < 0.01 −0.886 <0.01
IFNβ −0.769 <0.05 −0.781 < 0.05 −0.708 <0.05
IFNγ −0.235 NS −0.167 NS −0.244 NS
IL1α −0.501 NS −0.865 < 0.01 −0.821 <0.05
IL1β −0.579 NS −0.004 NS −0.432 NS
IL4 −0.327 NS −0.815 < 0.05 −0.638 NS
IL6 −0.775 <0.05a −0.917 < 0.01 −0.826 <0.05
IL8 −0.525 NS −0.838 < 0.05 −0.732 <0.05
IL10 −0.732 <0.05 −0.837 < 0.05 −0.824 <0.05
CXCL 10 −0.789 <0.05a −0.889 < 0.01 −0.887 <0.01
CCL2 0.000 NS −0.294 NS −0.083 NS
CXCL9 −0.819 <0.05 −0.918 < 0.01 −0.864 <0.01
CCL3 −0.239 NS −0.793 < 0.05 −0.084 NS
CCL5 −0.605 NS −0.201 NS −0.458 NS
TRAIL −0.713 <0.05 −0.555 NS −0.695 <0.05
VEGF −0.868 <0.01a −0.509 NS −0.906 <0.01
ICAM −0.683 <0.05a −0.910 < 0.01 −0.933 <0.01
IFNο −0.092 NS −0.772 < 0.05 −0.250 NS
MPO −0.014 NS −0.865 < 0.01 −0.167 NS
VCAM −0.723 <0.05a −0.973 < 0.001 −0.913 <0.01
MMP7 −0.823 <0.05 −0.966 < 0.001 −0.879 <0.01
MMP8 −0.386 NS −0.781 < 0.05 −0.562 NS
MMP9 −0.409 NS −0.733 < 0.05 −0.041 NS
Leptin −0.878 <0.01 −0.888 < 0.01 0.955 <0.001
IL17a −0.037 NS −0.914 < 0.01 −0.479 NS
a Mediators not present at greater concentrations in samples from the apical side that demonstrated signiﬁcant basolateral correlations with TEER.
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JEV infection and its eﬀect on increasing BBB permeability is in
agreement with our previous (Winter et al., 2004) and current work
(this study). We used a low titre of JEV (MOI= 1 cf. other published
studies) in all our experiments, which is much more likely to be close to
the lower viraemias thought to occur in human disease, and this was
suﬃcient to induce an increase in BBB permeability through the release
of cytokines and chemokines.
5. Conclusions
Taken together, our study suggests that infection of HBECs by JEV
leads to an initial production of viral particles that activates the brain
endothelium. Because we have seen limited JEV production in brain
endothelial cells, we postulate that the pro-inﬂammatory cytokine
milieu is the main driving force behind BBB disruption. Results from
many in vitro and in vivo studies conﬁrm that administration of cyto-
kines and/or chemokine either directly on the BBB (de Vries et al.,
1996; Wong et al., 2004; Rochfort & Cummins, 2015) or systemically
(Saija et al., 1995) leads to an increase in BBB permeability/reduction
in TEER, and inhibition/neutralising of these modulators reverses the
eﬀects (Deli et al., 2005; Abbott, 2000). Therefore, our data support the
hypothesis that release of inﬂammatory cytokines/chemokines from
HBECs and astrocytes in response to JEV infection adversely aﬀects BBB
integrity. Indeed, we have shown that dexamethasone treatment fol-
lowing JEV infection reduces the inﬂammation and restores BBB in-
tegrity. The use of dexamethasone and other corticosteroids in clinical
practice is limited by fears over their widespread immunosuppressive
eﬀects, which might allow uncontrolled viral replication. However, our
study has demonstrated that dexamethasone treatment does not lead to
increased levels of infectious JEV particles in culture. Targeted im-
munomodulatory therapies may prove useful in the future.
Our study is not without limitations. Cell culture models of the BBB
cannot mimic all the features of the in vivo BBB or indeed the neuro-
vascular unit, and there are limitations associated with simulating
Fig. 6. Dexamethasone treatment dampens the immune response.
The co-culture human BBB model was infected from the apical side with JEV (MOI= 1). Some cultures were treated with 2 μg/ml dexamethasone (Dex) from the
apical side immediately post infection. Supernatants were collected from both apical (black bars) and basolateral (white bars) side at 2 dpi for analysis by Multi-
Analyte ELISArray for IL6 (A-B), CCL5 (C–D) and CXCL10 (E–F) levels. Results are mean ± SE (n=3), Student's t-Test, comparing JEV and JEV+Dex; *P < 0.05,
**P < 0.01.
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natural viral infection. Currently no “gold standard” BBB model exists,
and relatively low tightness of HBEC monolayers compared to porcine
(Patabendige et al., 2013b) or bovine (Dehouck et al., 1990) brain
endothelial cells is still a challenge for some studies. As we still lack a
complete understanding of the in vivo BBB, ﬁrmly establishing features
of a “gold standard” model is diﬃcult (Helms et al., 2016). Never-
theless, human cell culture models can be powerful tools to investigate
host-pathogen interactions in more detail, and can be used to obtain
relevant human data when carefully designed to be “ﬁt for the purpose”
of predicting human response (Patabendige, 2012). Understanding the
complexities of the interactions of neuroinvasive viruses with the
human BBB is imperative for developing new therapies. Using a model
derived from human brain cells, we have tried to mimic the human
condition as closely as possible in laboratory conditions. However,
since we have not introduced immune cells into the system, the immune
cell-mediated suppression of virus production, and the im-
munosuppressive actions of dexamethasone on immune cell-mediated
response require further investigation. With advanced physiologically
relevant multi-cellular ﬂow-based 3D BBB models and increased
availability of human material from brain banks and commercial sup-
pliers, future research will be able to build up on these observations and
reduce the reliance on the use of animals.
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